Navigation Links
MiMedx Is Issued Four Additional U.S. Patents For Placental Tissue Grafts
Date:2/11/2013

ic tissue is very gentle to the tissue, and allows us to preserve the critical wound healing characteristics that are inherent in the amniotic tissue, and this yields an allograft with remarkable healing capabilities. This process does not decellularize the tissue, but rather retains those growth factors and cytokines that are critical to healing."

The MiMedx allografts produced from the Company's proprietary PURION® Process for amniotic membrane tissue can be stored at room temperature for five years without the need for refrigeration or freezing.  The grafts can be utilized right out of the package without a complicated thawing process.  These critical qualities of the MiMedx allografts allow hospitals, clinics and surgeons to effectively manage their inventory of allografts.

About the Company
MiMedx® is an integrated developer, manufacturer and marketer of patent protected regenerative biomaterial products and bioimplants processed from human amniotic membrane. "Innovations in Regenerative Biomaterials" is the framework behind our mission to give physicians products and tissues to help the body heal itself. Our biomaterial platform technologies include the device technologies HydroFix® and CollaFix™, and our tissue technologies, AmnioFix® and EpiFix®. Our tissue technologies are processed from human amniotic membrane that is derived from the donated placentas. Through our donor program, mothers delivering full-term Caesarean section births can elect in advance of delivery to donate the placenta in lieu of having it discarded as medical waste. We process the human amniotic membrane utilizing our proprietary Purion® Process, to produce a safe, effective and minimally manipulated implant for homologous use. MiMedx® is the leading supplier of amniotic tissue, having supplied over 120,000 allografts to date to distributors and OEMs for application in the Wound care, Surgical, Sports Medicine,
'/>"/>

SOURCE MiMedx Group, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. MiMedx Group, Inc. to Present at the 6th Annual Canaccord Genuity Cardiovascular, Aesthetics and Metabolic Disorders Conference
2. MiMedx Group Completes $5,000,000 Private Placement
3. MiMedx Group, Inc. Receives CE Certification for Its CollaFix™ Surgical Mesh CD
4. MiMedx to Present at American Academy of Orthopaedic Surgeons Annual Meeting
5. MiMedx Group Announces 2011 Results
6. MiMedx Signs Agreement with Systagenix for Global Distribution of EpiFix®
7. MiMedx Exceeds Revenue Goal for First Quarter of 2012
8. MiMedx Group Announces Record First Quarter Results
9. MiMedx Group, Inc. Announces Release Date for 2012 Second Quarter Results
10. MiMedx Group Announces Record Second Quarter Results
11. MiMedx Group to Present at the Canaccord Genuity Annual Growth Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... ... August 28, 2015 , ... Riordan-McKenna Institute ... announced today that the use of sterile, dehydrated amniotic tissue AlphaPATCH™ developed by ... otherwise non-healing surgical knee wound. , The case involved a 78-year-old male, who ...
(Date:8/28/2015)... ... ... launch of FireflySci Inc. (FFS) in early 2015, the company continues to shake up the ... Fonz in a lab coat and Large Marge have been posted on the company’s Facebook ... FireflySci is proud to be the only cuvette manufacturer is the world that has an ...
(Date:8/27/2015)... ... August 27, 2015 , ... The Kansas ... investment firms and animal health companies to hear from animal health companies with ... have also received licensing agreements or distribution contracts. This meeting is one ...
(Date:8/27/2015)... ... August 27, 2015 , ... Capital Edge Consulting , ... problems, is pleased to announce their ranking as one of the top 5000 companies ... fastest-growing private companies across the nation. , “It is truly an honor to be ...
Breaking Biology Technology:Dallas-Fort Worth Stem Cell Researchers Use Amniotic Tissue To Successfully Treat Non-Healing Surgical Wound 2Dallas-Fort Worth Stem Cell Researchers Use Amniotic Tissue To Successfully Treat Non-Healing Surgical Wound 3Dallas-Fort Worth Stem Cell Researchers Use Amniotic Tissue To Successfully Treat Non-Healing Surgical Wound 4Cuvette Manufacturer FireflySci Launches Back to School Deals with Complimentary Shipping On All Orders 2VetStem Biopharma, Inc. Among Seventeen Companies Selected to Present at the KC Animal Health Investment Forum on September 1st 2015 2VetStem Biopharma, Inc. Among Seventeen Companies Selected to Present at the KC Animal Health Investment Forum on September 1st 2015 3Capital Edge Consulting Makes Inc. 5000 List of America’s Fastest-Growing Private Companies 2Capital Edge Consulting Makes Inc. 5000 List of America’s Fastest-Growing Private Companies 3
... Receive Funding, From Allied Minds to Commercialize Novel Technology for the ... ... Aliquots, BOSTON, July 2 Allied Minds, a pre-seed investment,corporation ... Development, and Northeastern,University announce the creation of CryoXtract Instruments, LLC, a ...
... levels as a possible ... predictor of clinical activity -, TORONTO, ... ("Lorus" or the "Corporation"), a biopharmaceutical company,specializing in the research ... cancer, today announced publication by,an Ohio State University (OSU) clinical ...
... Microfluidic Systems Inc.,(MFSI) announced today that it has ... of Microfluidic - Bioagent Autonomous Networked Detector,(M-BAND). This ... funded phases by the DHS,Science and Technology Directorate ... allow for low-volume production of automated,systems for extended ...
Cached Biology Technology:Investment Firm Allied Minds to Commercialize New Frozen Aliquotter Technology with Two Local Major Universities. 2Lorus Therapeutics Announces Publication of a Clinical Study Demonstrating Encouraging Results with LOR-2040 in Combination with Cytarabine in Patients with Acute Myeloid Leukemia (AML) 2Lorus Therapeutics Announces Publication of a Clinical Study Demonstrating Encouraging Results with LOR-2040 in Combination with Cytarabine in Patients with Acute Myeloid Leukemia (AML) 3Lorus Therapeutics Announces Publication of a Clinical Study Demonstrating Encouraging Results with LOR-2040 in Combination with Cytarabine in Patients with Acute Myeloid Leukemia (AML) 4Lorus Therapeutics Announces Publication of a Clinical Study Demonstrating Encouraging Results with LOR-2040 in Combination with Cytarabine in Patients with Acute Myeloid Leukemia (AML) 5Microfluidic Systems Receives Continued Funding From the Department of Homeland Security (DHS) Toward the Commercial Production of Autonomous Airborne Pathogen Detection Systems 2Microfluidic Systems Receives Continued Funding From the Department of Homeland Security (DHS) Toward the Commercial Production of Autonomous Airborne Pathogen Detection Systems 3
(Date:8/12/2015)... Aug. 12, 2015   MedNet Solutions , an ... spectrum of clinical research, is proud to announce that ... comprehensive SaaS-based eClinical technology platform, has led the way ... two quarters of 2015.   Q2 2015 and Q1 ... measured by contract value sold in the company,s 15 ...
(Date:8/12/2015)... , Aug. 12, 2015  New research unveiled ... attack Android phones to steal users, fingerprints. Information ... availability of fingerprint scanners on mobile devices, making ... To secure biometrics on mobile devices, HYPR Corp. ... these convenient authentication systems with strong cryptographic security. ...
(Date:8/11/2015)... Today, ZUK announced its Android smartphone Z1, ... expected revenues in 2015 that relate to sales of FPC1155 for ... approximately 2,200 MSEK for 2015. Jörgen Lantto, CEO of ... smartphone manufacturer in China and ... 155 for Z1 , ...
Breaking Biology News(10 mins):MedNet Solutions Experiences Explosive Corporate Growth 2HYPR Corp. Addresses Android Vulnerability That Exposes Ecosystem-wide Biometric Security Challenges 2HYPR Corp. Addresses Android Vulnerability That Exposes Ecosystem-wide Biometric Security Challenges 3FPC's Touch Fingerprint Sensor FPC1155 in ZUK's Smartphone Z1 2
... the form of tiny grains resembling powder, which is ... from the European Synchrotron Radiation Facility (ESRF) and the ... the synchrotron to determine the structure of microcrystal grains ... a thousand on the size of the analysable samples, ...
... may help reduce the risk of pancreatic cancer, says ... found naturally in apples and onions, has been identified ... and reducing the risk of pancreatic cancer. Although ... smokers who consumed foods rich in flavonols had a ...
... Children,s Research Hospital settled a century-old debate on the ... and capillaries critical to various essential housekeeping functions in ... development of new therapies for lymphatic system disorders, the ... various mouse models to demonstrate that the lymphatic vasculature ...
Cached Biology News:Unveiling the structure of microcrystals 2Naturally-occurring apple compounds reduce risk of pancreatic cancer 2St. Jude settles century-old debate on origin of mammalian network of lymphatic vessels 2St. Jude settles century-old debate on origin of mammalian network of lymphatic vessels 3